Obesity/Glucose Metabolic Disorders - Eos SENOLYTIX

Obesity/Glucose Metabolic Disorders

Greater lean-body-mass decline with tirzepatide than semaglutide in routine care revealed by body-composition digital phenotyping

April 13, 2026

Unintended risks of sarcopenic obesity during weight-loss interventions in older people

February 5, 2026

Muscle-preserving therapies in the era of pharmacological weight loss

January 2, 2026

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis

December 22, 2024

Inhibition Of IL-11 Signalling Extends Mammalian Healthspan and Lifespan

June 11, 2024

Prophylactic and Long-Lasting Efficacy of Senolytic CAR T Cells Against Age-Related Metabolic Dysfunction

January 24, 2024

Once-Weekly Semaglutide in Adults with Overweight or Obesity

March 18, 2021

Targeting Senescent Cells Alleviates Obesity‐Induced Metabolic Dysfunction

January 25, 2019

Categories

Archives

© 2026 Eos SENOLYTIX.